Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Cipla Ltd

| Q2 FY26 Earnings Conference Call

BULLISH SENTIMENT

Report Source

⬤30th Oct 25

Summary : Cipla delivered record Q2 revenue with strong margins, driven by diversified growth across key markets and strategic new product launches, despite a revised EBITDA margin outlook.

Management Perspective positive : Management consistently highlighted 'all-time high quarterly revenue,' 'robust EBITDA margin,' 'strong double-digit growth,' and 'significant milestone' launches. They expressed confidence in future growth and market-beating performance.

Concall Report Analysis & Insights

Business Overview

  1. Q2 FY26 revenue reached an all-time high of INR7,589 crores, growing 8% year-on-year.
  2. EBITDA margin stood at 25%, with a gross margin of 67% after material costs.
  3. One-India business grew 7% year-on-year, strengthening chronic mix to 61.8%.
  4. U.S. Generics revenue was $233 million, with Albuterol MDI becoming #1 with 22% market share.
  5. One Africa grew 5% (USD) and EMEU delivered its strongest quarterly revenue at $110 million (USD).

Future Growth Prospects

  1. Entering the obesity care segment with the launch of Yurpeak (tirzepatide) through Eli Lilly partnership.
  2. Upcoming launches include Elbicip (gastroenterology), Aprela (dermatology), and anti-infectives.
  3. Expect four major U.S. respiratory assets and three peptide assets, including liraglutide, by CY '26.
  4. Focus on enhancing commercial execution and accelerating new product introductions in North America.
  5. Intends to expand biosimilar portfolio through own development and partnerships.

Management Insights

  1. Achieved all-time high quarterly revenue and robust EBITDA margin, driven by diversified portfolio.
  2. Committed to innovation and future readiness, accelerating filings to capitalize on opportunities.
  3. Dedicated to making healthcare more affordable and accessible, aligning with government reforms.
  4. U.S. manufacturing facility at Bommasandra received VAI qualification from FDA.
  5. Tirzepatide is a significant market-shaping opportunity with strong science.

Signs of Skepticism

  1. Management declined to disclose specific terms of the Eli Lilly tirzepatide agreement.
  2. Specific revenue guidance for the U.S. market for the next quarter was not provided.
  3. Specific timelines for generic QVAR launch were not disclosed.
  4. Management deferred FY '27 EBITDA margin guidance to the next quarter.
  5. Specific market share targets for nanopaclitaxel were not given.

Risk Factors

  1. GST rate transition caused a brief disruption in sales trends, resolved within the quarter.
  2. Generic Revlimid contribution to U.S. revenue will be very small in Q3 FY26.
  3. Timing gaps may occur before the full benefit of new U.S. launches is realized.
  4. Revised full year EBITDA margin guidance slightly lower to 22.75%-24% from 23.5%-24.5%.
  5. Q4 is historically the lowest quarter for sales and margins.

Good To Know

  1. Achin Gupta appointed designated CEO effective January 1, 2026, assuming full responsibilities April 1, 2026.
  2. R&D spend is trending higher this year, about 0.5% of revenue above planned due to new programs.
  3. The effective tax rate for the quarter was 27%.
  4. Net cash balance stood at INR9,901 crores after adjusting for cash outflow and dividend payout.
  5. U.S. manufacturing costs are higher than India, primarily due to labor expenses.

Key Drivers

  1. New U.S. respiratory product launches.
  2. Entry into the obesity care segment.
  3. Strong growth in chronic therapies.
  4. Expanding biosimilar product portfolio.

Key Analyst Discussions

Competitive Environment

  1. Cipla is the exclusive partner for Lilly's tirzepatide in India, aiming to shape the market.
  2. Semaglutide market is expected to be shared by many players upon genericization.
  3. Lanreotide market share is expected to continue growing, despite potential near-term competition.
  4. Abraxane launch initially faced an oversupplied market, now improving.
  5. Cipla aims to increase scale and competitiveness in generics across key markets.

Market Trends & Consumer Behavior

  1. Obesity and diabetes segments present significant market opportunities.
  2. Tirzepatide targets a distinct patient set compared to semaglutide, leveraging superior science.
  3. Domestic formulation business market growth is estimated at 8%-9%.
  4. Chronic conditions related to lifestyle and changing demographics are driving volume growth.
  5. Respiratory remains a cornerstone, with strong traction for triple combo products.

Financial Highlights

  1. Revised full year EBITDA margin guidance to 22.75%-24% from previous 23.5%-24.5%.
  2. Revlimid contribution to U.S. revenue will be significantly lower in Q3 FY26.
  3. Gross margin decline in Q2 attributed to price cuts, Africa tender business, and R&D material costs.
  4. R&D spend increased due to new programs and accelerated filings, impacting margins.
  5. Q4 is historically the lowest quarter for both sales and margins.

Product Composition

  1. GLP-1 (tirzepatide) involves procuring API and fill-finish through CMOs.
  2. Respiratory, anti-diabetes, cardiac, urology, and dermatology therapies are key growth drivers.
  3. Consumer Health business maintains leadership in Nicotex, Omnigel, and Cipladine segments.
  4. Expanding across CNS, urology, dermatology, and anti-infectives with new launches.
  5. Tirzepatide will have a dedicated field force, separate from other products like semaglutide.

Strategic Considerations

  1. New CEO Achin Gupta will develop strategy, but continuity in purpose and respiratory leadership expected.
  2. Focus on increasing scale and competitiveness in generics across India, U.S., ROW, and South Africa.
  3. Exploring innovation opportunities and expanding product introductions in the R&D pipeline.
  4. Considering adding more biosimilar products to the portfolio through internal development and partnerships.
  5. U.S. manufacturing facilities derisk future respiratory product launches.